Truist Securities Reiterates Fate Therapeutics (FATE) at Buy, Highlights Multiple Upcoming Readouts and Current Price Level
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $125.00 price target on Fate Therapeutics (NASDAQ: FATE)The analyst quotes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
